Kane Biotech Secures Health Canada Approval for Revyve Antimicrobial Wound Gel

WINNIPEG, MANITOB A – November 14, 2024 - Kane Biotech Inc., a biotechnology company specializing in microbial biofilm research and development, announced today that it has received Health Canada approval for its revyve antimicrobial wound gel as a Class 2 Medical Device.

This approval permits Kane Biotech to immediately promote and sell the product in Canada, marking an important milestone for the company. "We are thrilled to bring this much-needed product to Canada," said Marc Edwards, President & CEO of Kane Biotech. "Congratulations to our team for achieving this significant success and continuing to execute on our strategic plan."

The revyve Antimicrobial Wound Gel is developed by Kane Biotech to prevent and remove microbial biofilms, which can cause severe infections in wounds. The product has already shown promising results in clinical trials.

Kane Biotech Inc., with its portfolio of biotechnologies, intellectual property, and products, is a leader in the field of microbial biofilm research and development. The company's products, including DispersinB, coactiv+, DermaKB, and revyve, are designed to prevent and remove microbial biofilms.

"We are excited to bring our expertise and technologies to Canada," said Marc Edwards. "We look forward to working with healthcare professionals and organizations to make a positive impact on wound care."

The company is listed on the TSX Venture Exchange under the symbol KNE and on the OTCQB Venture Market under the symbol KNBIF.

Contact: Marc Edwards President & CEO Kane Biotech Inc. medwards@kanebiotech.com

Ray Dupuis Chief Financial Officer Kane Biotech Inc. rdupuis@kanebiotech.com